Streetbeat News

Price Targets

BAC

Unusual options activity has been observed for Bank of America (NYSE:BAC) with 12 options trades spotted, 75% of which are bearish. Whales have been targeting a price range of $25.0 to $28.0 for BAC over the last 3 months. Evercore ISI Group maintains an Outperform rating with a price target of $35.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 3:16 pm

NVDA

NVIDIA Corp (NASDAQ:NVDA) shares are volatile ahead of the company's Q1 results due on Wednesday. Analysts have raised price targets, with the stock up more than 110% since the start of the year. The company is expected to report earnings of 92 cents per share on quarterly revenue of $6.52 billion.

Portfolio Pulse from Adam Eckert

May 23, 2023 | 3:12 pm

CRSP

CRISPR Therapeutics shares are trading higher after Citigroup maintained a Neutral rating on the stock and raised its price target from $55 to $70.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 3:11 pm

RH

In the last quarter, 12 analysts provided ratings for RH (NYSE:RH) with an average 12-month price target of $266.25, a decrease of 15.04% from the previous average of $313.40. The ratings include 2 bullish, 10 indifferent, and no bearish ratings.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 3:05 pm

HUBS

In the last quarter, 22 analysts rated HubSpot (NYSE:HUBS) with 8 bullish, 13 somewhat bullish, and 1 indifferent. The average 12-month price target is $494.68, an 8.69% increase from the previous average of $455.11.

Portfolio Pulse from Benzinga Insights

May 23, 2023 | 3:04 pm

AIG

Citigroup analyst Michael Ward maintains a Buy rating on American Intl Gr (NYSE:AIG) and raises the price target from $70 to $73.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 2:34 pm

AJG

Citigroup analyst Michael Ward maintains a Buy rating on Arthur J. Gallagher (NYSE:AJG) and raises the price target from $232 to $247.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 2:33 pm

AVPT

Citigroup analyst Fatima Boolani maintains a Neutral rating on AvePoint (NASDAQ:AVPT) and raises the price target from $4.7 to $5.8.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 2:31 pm

IMVT

B of A Securities analyst Jason Gerberry maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $26 to $28.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 2:28 pm

IMVT

Guggenheim analyst Yatin Suneja maintains a Buy rating on Immunovant (NASDAQ:IMVT) and raises the price target from $30 to $32.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 2:27 pm